Diagnostics and Therapeutics in Targeting HER2 Breast Cancer: A Novel Approach (original) (raw)
Improved Aptamers for the Diagnosis and Potential Treatment of HER2-Positive Cancer
MArlies Gijs
Pharmaceuticals (Basel, Switzerland), 2016
View PDFchevron_right
Preclinical screening of anti-HER2 nanobodies for molecular imaging of breast cancer
Nick Devoogdt, I. Vaneycken, Cécile Vincke
The FASEB Journal, 2011
View PDFchevron_right
Targeting breast carcinoma with radioiodinated anti-HER2 Nanobody
Marek Pruszyński, Eftychia Koumarianou
Nuclear Medicine and Biology, 2013
View PDFchevron_right
TNBC Challenge: Oligonucleotide Aptamers for New Imaging and Therapy Modalities
simona camorani
Pharmaceuticals, 2018
View PDFchevron_right
A HER2-targeted RNA aptamer molecule labeled with 99mTc for single-photon imaging in malignant tumors
Kambiz Varmira, Seyed Jalal Hosseinimehr, Seyed Abedi
Nuclear Medicine and Biology, 2013
View PDFchevron_right
Tumor Imaging Using a Picomolar Affinity HER2 Binding Affibody Molecule
Anna Orlova, Mikaela Magnusson, Vladimir Tolmachev
Cancer Research, 2006
View PDFchevron_right
HER2 targeting as a two-sided strategy for breast cancer diagnosis and treatment: Outlook and recent implications in nanomedical approaches
Serena Mazzucchelli
Pharmacological Research, 2010
View PDFchevron_right
Selection of DNA aptamers for extra cellular domain of human epidermal growth factor receptor 2 to detect HER2 positive carcinomas
ARGHYA SETT
View PDFchevron_right
Molecular Imaging of HER2-Expressing Malignant Tumors in Breast Cancer Patients Using Synthetic 111In- or 68Ga-Labeled Affibody Molecules
Joachim Feldwisch
2016
View PDFchevron_right
Biodistribution of Novel 68Ga-Radiolabelled HER2 Aptamers in Mice
MArlies Gijs
Journal of Nuclear Medicine & Radiation Therapy, 2016
View PDFchevron_right
First-in-Human Molecular Imaging of HER2 Expression in Breast Cancer Metastases Using the 111In-ABY-025 Affibody Molecule
Joachim Feldwisch
Journal of Nuclear Medicine, 2014
View PDFchevron_right
111In-benzyl-DTPA-ZHER2:342, an affibody-based conjugate for in vivo imaging of HER2 expression in malignant tumors
Fredrik Frejd
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2006
View PDFchevron_right
Evaluation of human epidermal growth factor receptor 2 in breast cancer with a novel specific aptamer
James Yahaya
Cellular & molecular immunology, 2015
View PDFchevron_right
HER2-directed antibodies, affibodies and nanobodies as drug-delivery vehicles in breast cancer with a specific focus on radioimmunotherapy and radioimmunoimaging
Agnieszka Morgenroth
European Journal of Nuclear Medicine and Molecular Imaging
View PDFchevron_right
Improved Tumor Targeting of Anti-HER2 Nanobody Through N-Succinimidyl 4-Guanidinomethyl-3-Iodobenzoate Radiolabeling
Eftychia Koumarianou, Marek Pruszyński
Journal of Nuclear Medicine, 2014
View PDFchevron_right
Synthesis, Preclinical Validation, Dosimetry, and Toxicity of 68Ga-NOTA-Anti-HER2 Nanobodies for iPET Imaging of HER2 Receptor Expression in Cancer
Nick Devoogdt, M. Keyaerts, Matthias D'Huyvetter, I. Vaneycken, Cécile Vincke
Journal of Nuclear Medicine, 2013
View PDFchevron_right
Conjugate for In Vivo Imaging of HER2 Expression in Malignant Tumors
Kis Dota
View PDFchevron_right
HER-2-Targeted Nanoparticles for Breast Cancer Diagnosis and Treatment
Francesco Mainini
Cancers
View PDFchevron_right
Phase I study of 68Ga-HER2-Nanobody for PET/CT assessment of HER2-expression in breast carcinoma
Ilse Vaneycken
Journal of Nuclear Medicine
View PDFchevron_right
HER2-Positive Tumors Imaged Within 1 Hour Using a Site-Specifically 11C-Labeled Sel-Tagged Affibody Molecule
Erik Samén
Journal of Nuclear Medicine, 2012
View PDFchevron_right
64 Cu-Labeled Affibody Molecules for Imaging of HER2 Expressing Tumors
Jack Webster
Molecular Imaging and …, 2010
View PDFchevron_right
Synthetic Affibody Molecules: a Novel Class of Affinity Ligands for Molecular Imaging of HER2-Expressing Malignant Tumors
thuy tran
Cancer research, 2007
View PDFchevron_right
In Vitro Characterization of a Bivalent Anti-HER-2 Affibody with Potential for Radionuclide-Based Diagnostics
Grégory ADAMS
Cancer Biotherapy and Radiopharmaceuticals, 2005
View PDFchevron_right